规格
|
Alternate Agonists:
|
Docosahexaenoic Acid, Phytanic Acid, All-trans-retinoic acid |
Antagonists:
|
RO 41-5253 |
Assay Entry:
|
Cell-based beta lactamase reporter gene |
Cell State:
|
Dividing Cells |
Druggable Target:
|
Nuclear Receptors |
Primary Agonist:
|
9-cis-retinoic acid |
Product Line:
|
GeneBLAzer® |
Reporter Gene:
|
BLA (Beta-Lactamase) |
Shipping Condition:
|
Room Temperature |
System Type:
|
GeneBLAzer™ |
Target Entry:
|
AR, NR3C4 |
Detection Method:
|
Fluorescent |
储存
|
Shipping: Dry IceStorage: -80°C/Liquid NitrogenContains: AR-UAS-bla GripTite™ cells (K1698) |
AR-UAS-bla GripTite™ 293 cells contain the ligand-binding domain (LBD) of the rat Androgen receptor (AR) fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer®UAS-bla GripTite™ 293 cell line. GeneBLAzer®UAS-bla GripTite™ cells stably express a beta-lactamase reporter gene under the transcriptional control of an upstream activator sequence (UAS). When an agonist binds to the LBD of the GAL4 (DBD)-AR (LBD) fusion protein, the protein binds to the UAS, resulting in expression of beta-lactamase. Division Arrested (DA) cells are available in two configurations- an Assay Kit (which includes cells and sufficient substrate to analyze 1 x 384-well plate), and a tube of cells sufficient to analyze 10 x 384-well plates. AR-UAS-bla GripTite™ 293 cells are functionally validated for Z' and EC50 concentrations of R1881. Cells have been tested for assay performance under variable conditions, including DMSO concentration, cell number, stimulation time, and substrate loading time (data available upon request). Additional testing data using alternate stimuli are also available.